These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22704482)

  • 1. Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset type II glycogenosis?
    Ravaglia S; De Filippi P; Pichiecchio A; Ponzio M; Saeidi Garaghani K; Poloni GU; Bini P; Danesino C
    Mol Genet Metab; 2012 Sep; 107(1-2):104-10. PubMed ID: 22704482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism in exercise genes and respiratory function in late-onset Pompe disease.
    Ravaglia S; Malovini A; Cirio S; Danesino C; De Filippi P; Moggio M; Mongini T; Maggi L; Servidei S; Vianello A; Toscano A; Tonin P; Maioli MA; Parini R; Filosto M; Crescimanno G; Arceri S; Piran M; Carlucci A
    J Appl Physiol (1985); 2021 Dec; 131(6):1762-1771. PubMed ID: 34734785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.
    Kuperus E; van der Meijden JC; In 't Groen SLM; Kroos MA; Hoogeveen-Westerveld M; Rizopoulos D; Martinez MYN; Kruijshaar ME; van Doorn PA; van der Beek NAME; van der Ploeg AT; Pijnappel WWMP
    PLoS One; 2018; 13(12):e0208854. PubMed ID: 30532252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human angiotensin-converting enzyme I/D and alpha-actinin 3 R577X genotypes and muscle functional and contractile properties.
    McCauley T; Mastana SS; Hossack J; Macdonald M; Folland JP
    Exp Physiol; 2009 Jan; 94(1):81-9. PubMed ID: 18676575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE and ACTN3 genes and muscle phenotypes in nonagenarians.
    Bustamante-Ara N; Santiago C; Verde Z; Yvert T; Gómez-Gallego F; Rodríguez-Romo G; González-Gil P; Serra-Rexach JA; Ruiz JR; Lucia A
    Int J Sports Med; 2010 Apr; 31(4):221-4. PubMed ID: 20148371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes before and after strength training.
    Erskine RM; Williams AG; Jones DA; Stewart CE; Degens H
    Scand J Med Sci Sports; 2014 Aug; 24(4):642-8. PubMed ID: 23384112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between angiotensin converting enzyme insertion/deletion genotype and exercise training on knee extensor strength in older individuals.
    Giaccaglia V; Nicklas B; Kritchevsky S; Mychalecky J; Messier S; Bleecker E; Pahor M
    Int J Sports Med; 2008 Jan; 29(1):40-4. PubMed ID: 17614015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin I-converting enzyme and α-actinin-3 gene polymorphisms on sport performance.
    Gunel T; Gumusoglu E; Hosseini MK; Yilmazyildirim E; Dolekcap I; Aydinli K
    Mol Med Rep; 2014 Apr; 9(4):1422-6. PubMed ID: 24566537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Dimopoulos F; Papadimas GK; Papadopoulos C; Spengos K; Fatouros I; Kavouras SA; Manta P
    Mol Genet Metab; 2011 Nov; 104(3):279-83. PubMed ID: 21640624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response.
    Ravaglia S; Pichiecchio A; Ponzio M; Danesino C; Saeidi Garaghani K; Poloni GU; Toscano A; Moglia A; Carlucci A; Bini P; Ceroni M; Bastianello S
    J Inherit Metab Dis; 2010 Dec; 33(6):737-45. PubMed ID: 20844963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACE I/D, ACTN3 R577X, PPARD T294C and PPARGC1A Gly482Ser polymorphisms and physical fitness in Taiwanese late adolescent girls.
    Chiu LL; Chen TW; Hsieh SS; Hsieh LL
    J Physiol Sci; 2012 Mar; 62(2):115-21. PubMed ID: 22247001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-phenotype correlation in Pompe disease, a step forward.
    De Filippi P; Saeidi K; Ravaglia S; Dardis A; Angelini C; Mongini T; Morandi L; Moggio M; Di Muzio A; Filosto M; Bembi B; Giannini F; Marrosu G; Rigoldi M; Tonin P; Servidei S; Siciliano G; Carlucci A; Scotti C; Comelli M; Toscano A; Danesino C
    Orphanet J Rare Dis; 2014 Aug; 9():102. PubMed ID: 25103075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New frontiers in sport training: genetics and artistic gymnastics.
    Morucci G; Punzi T; Innocenti G; Gulisano M; Ceroti M; Pacini S
    J Strength Cond Res; 2014 Feb; 28(2):459-66. PubMed ID: 23698081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis.
    Ravaglia S; Danesino C; Moglia A; Costa A; Cena H; Maccarini L; Carlucci A; Pichiecchio A; Bini P; De Filippi P; Rossi M
    Eur J Neurol; 2010 Jul; 17(7):957-62. PubMed ID: 20158513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
    Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
    Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACE ID genotype affects blood creatine kinase response to eccentric exercise.
    Yamin C; Amir O; Sagiv M; Attias E; Meckel Y; Eynon N; Sagiv M; Amir RE
    J Appl Physiol (1985); 2007 Dec; 103(6):2057-61. PubMed ID: 17885020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.